Enes Yeşilbaş, Medical Oncologist at Ankara Etlik City Hospital, shared on X:
“Our new study is now published in JCO Global Oncology!
Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome:
A Prospective Real-World Study
In this prospective, two-center real-world study of 151 patients receiving capecitabine-based therapy, we evaluated prophylactic topical diclofenac for the prevention of clinically significant hand-foot syndrome (HFS).
Grade ≥2 HFS occurred in 16.9% (12/71) with topical diclofenac versus 13.8% (11/80) with active monitoring (OR 1.28; 95% CI, 0.52–3.10; P = .591).
Our findings showed that prophylactic topical diclofenac did not reduce clinically significant HFS or delay its onset in routine clinical practice, adding prospective real-world evidence to this evolving area of supportive oncology.
Special thanks to our first author, Dr. Orhun Akdoğan and our mentor, Dr. Osman Sütcüoğlu for their leadership and guidance, and to our entire team for their valuable contributions.
Grateful to be part of this collaboration!”
Title: Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study
Authors: Orhun Akdogan, Sevgi Eryildiz Yucel, Ozan Yazici, Kadriye Bir Yucel, Fatih Gurler, Galip Can Uyar, Gözde Savas, Enes Yesilbas, Ugur Coskun, Kadriye Baskurt, Aytug Uner, Ahmet Ozet, Berna Oksuzoglu, Nuriye Ozdemir, Osman Sutcuoglu
Read the Full Article.
Other articles about JCO Global Oncology on OncoDaily.
